Article
Hematology
Courteney Wiredu, Norrisa Haynes, Carmen Guerra, Bonnie Ky
Summary: Active malignancy increases the risk of developing venous thromboembolism (VTE) by four- to seven-fold. Race and ethnicity play a role in VTE risk, with black patients having a higher risk and Asian/Pacific Islanders having a lower risk. Understanding the biological and sociological factors behind these disparities can lead to better health outcomes for underserved populations.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Hematology
Alexander Cohen, Virginia Noxon, Amol Dhamane, Robert Bruette, Shrushti Shah, Dionne M. Hines, Tamuno Alfred, Xuemei Luo
Summary: This study compared the risks of recurrent venous thromboembolism (VTE), major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) among cancer patients with brain cancer and other types of cancer who initiated apixaban, low molecular weight heparin (LMWH), or warfarin. The results showed that apixaban was associated with a lower risk of these adverse events compared to LMWH and warfarin, and there were no significant differences in the anticoagulant treatment effects between patients with brain cancer and those with other cancer.
THROMBOSIS RESEARCH
(2023)
Article
Hematology
Jakob M. Riedl, Esther Schwarzenbacher, Florian Moik, Lena Horvath, Antonia Gantschnigg, Felix Renneberg, Florian Posch, Dominik A. Barth, Michael Stotz, Martin Pichler, Stefan Hatzl, Simon Fandler-Hofler, Paul Gressenberger, Thomas Gary, Philipp J. Jost, Richard Greil, Cihan Ay, Angela Djanani, Armin Gerger, Konstantin Schlick
Summary: This study aimed to comprehensively characterize the incidence, risk factors, and outcomes of VTE and ATE in aPC patients undergoing palliative first-line chemotherapy. Results showed that VTE diagnosis was associated with increased mortality and cancer progression risk, while the impact of ATE on mortality was numerically but not statistically significant.
THROMBOSIS AND HAEMOSTASIS
(2022)
Review
Hematology
Thita Chiasakul, Rushad Patell, Anthony Maraveyas, Marc Carrier, Jeffrey Zwicker
Summary: The incidence of VTE reported in chemotherapy RCTs in pancreatic cancer is significantly lower than what is reported in thromboprophylaxis studies. This indicates a lack of recognition of VTE in chemotherapeutic trials and underscores the importance of standardizing approaches to monitoring and reporting VTE in clinical trials.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Medicine, General & Internal
Landon L. Chan, Ky Lam, Daisy C. M. Lam, Ym Lau, L. Li, Kelvin K. C. Ng, Raymond S. Y. Tang, Stephen L. Chan
Summary: This study investigated the risk factors for thromboembolism (TE) and its impact on overall survival in a Chinese population with pancreatic cancer. The incidence of TE was found to be low, and stage IV disease was identified as a significant risk factor. TE and its treatment did not affect overall survival.
HONG KONG MEDICAL JOURNAL
(2023)
Article
Hematology
Randa G. Hanna-Sawires, Jesse Groen, Alexander Hamming, Rob A. E. M. Tollenaar, Wilma E. Mesker, Saskia A. C. Luelmo, Alexander L. Vahrmeijer, Bert A. Bonsing, Henri H. Versteeg, F. A. Klok, J. Sven D. Mieog
Summary: VTE in patients with pancreatic cancer is stage-dependent, with most cases occurring in advanced stages of the disease after cessation of active treatment. Stage IV pancreatic cancer is a predictor for VTE, while biliary drainage and tumor resection are protective factors. VTE is not directly associated with worse survival outcomes.
THROMBOSIS RESEARCH
(2021)
Article
Hematology
Florian Moik, Gerald Prager, Johannes Thaler, Florian Posch, Sarah Wiedemann, Theresa Schramm, Cornelia Englisch, Nigel Mackman, Ingrid Pabinger, Cihan Ay
Summary: The occurrence of VTE in pancreatic cancer patients is associated with shorter overall survival and progression-free survival. Higher levels of D-dimer, extracellular vesicle-tissue factor activity, PAI-1, and sP-selectin are independently prognostic for increased mortality. Furthermore, D-dimer can predict response to palliative chemotherapy.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2021)
Article
Cell & Tissue Engineering
Chenyun Song, Xinyu Chen, Jixin Ma, Hada Buhe, Yang Liu, Hexige Saiyin, Lixiang Ma
Summary: We report a pancreatic cancer nerve invasion model that merges human brain organoids with mouse pancreatic cancer organoids. The results showed that the mouse pancreatic cancer organoids tend to invade the human brain organoids, leading to increased proliferation of neuronal progenitor cells, intensified apoptosis of neurons, and increased expression of inflammatory molecules. This model can be applied to study the molecular mechanism of nerve invasion and screen therapeutic strategies.
JOURNAL OF TISSUE ENGINEERING
(2023)
Review
Oncology
R. A. L. Willems, N. Michiels, V. R. Lanting, S. Bouwense, B. L. J. van den Broek, M. Graus, F. A. Klok, B. Groot Koerkamp, B. de Laat, M. Roest, J. W. Wilmink, N. van Es, J. S. D. Mieog, H. ten Cate, J. de Vos-Geelen
Summary: In the past, patients with pancreatic ductal adenocarcinoma often underwent immediate surgery for tumor resection. Now, more and more patients receive chemotherapy (radiotherapy) before surgery. It is known that pancreatic cancer patients have a higher risk of developing thrombosis. However, the incidence of thrombosis in patients with pancreatic cancer during neoadjuvant chemotherapy is not well-studied. Few studies have investigated VTE incidence in this population, and it is unclear if these patients should use perioperative thromboprophylaxis. This narrative review summarizes the current evidence.
Article
Oncology
Satoshi Kobayashi, Shiro Koizume, Tomoko Takahashi, Makoto Ueno, Ritsuko Oishi, Shuhei Nagashima, Yusuke Sano, Taito Fukushima, Shun Tezuka, Manabu Morimoto, Sho Nakamura, Hiroto Narimatsu, Wolfram Ruf, Yohei Miyagi
Summary: Tissue factor levels are an independent predictive factor for cancer-associated thromboembolism in patients with pancreatic cancer.
Article
Oncology
F. Couturaud, I. Mahe, J. Schmidt, J-C. Gleize, T. Lafon, A. Saighi, F. Sedjelmaci, L. Bertoletti, P. Mismetti
Summary: This study aimed to provide data on the number of hospitalized VTE events among cancer patients with different types of cancer and their hospital management, and to estimate the burden of disease and the hospital burden of cancer-related VTE. The findings offer guidance on future research on VTE prophylaxis in patients with active cancer.
Article
Hematology
Takahito Suzuki, Reina Hori, Kazutaka Takeuchi, Ryo Yamamura, Hiromasa Katoh, Yoshihiro Noji, Masato Yamaguchi, Susumu Fujino
Summary: The study found a high incidence of VTE in patients with PDAC in Japan, with the VTE group having significantly more patients with a body mass index >25 kg/m(2) and a higher rate of chemotherapy compared to the non-VTE group. However, VTE may not have a significant effect on the prognosis of PDAC.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2021)
Review
Oncology
Oscar Y. Y. Franco-Rocha, Kimberly A. A. Lewis, Kayla D. D. Longoria, Alexa De La Torre Schutz, Michelle L. L. Wright, Shelli R. R. Kesler
Summary: This scoping review synthesized the available literature on cancer-related cognitive impairment (CRCI) in racial and ethnic minority populations. The findings suggest that there are disparities in CRCI among racial and ethnic minoritized individuals, with Black and non-white patients being more likely to experience CRCI compared to their white counterparts. The study suggests the need for standardized guidelines in measuring and reporting the racial and ethnic composition of research samples, differentiation of CRCI findings by racial and ethnic subgroups, consideration of the influence of structural racism on health outcomes, and development of strategies to promote the participation of racial and ethnic minority groups.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Hematology
Chelsea Howie, Craig Erker, Bruce Crooks, Paul Moorehead, Ketan Kulkarni
Summary: The study found that pediatric patients with CNS tumors have a significantly lower incidence of VTE compared to those with non-CNS cancers. An increase in treatment intensity rating significantly increased the odds of developing VTE.
THROMBOSIS RESEARCH
(2021)
Article
Hematology
Lauren Laderman, Krishnalatha Sreekrishnanilayam, Ramesh K. K. Pandey, Elizabeth Handorf, Aryeh Blumenreich, Kristen A. A. Sorice, Shannon M. M. Lynch, Khadija Cheema, Lavanya Nagappan, Iberia R. R. Sosa, Efrat Dotan, Namrata Vijayvergia
Summary: Background: Pancreatic cancer (PC) has a high risk of venous thromboembolism (VTE), but there is a lack of verified risk assessment models (RAMs) for metastatic pancreatic cancer (mPC). Methods: This retrospective study investigated a cohort of mPC patients treated at an academic cancer center and found a VTE incidence of 17.5%. Survival analysis showed that VTE predicted poorer outcomes, with a median OS of 10.5 months in the VTEmets group compared to 13.4 months in the non-VTE group. Advanced stage disease was identified as the strongest risk factor. Conclusions: These results highlight the significant burden of VTE in mPC and the importance of risk stratification and thromboprophylaxis in this population.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
E. O. Artemenko, S. I. Obydennyi, K. S. Troyanova, G. A. Novichkova, D. Y. Nechipurenko, M. A. Panteleev
Summary: In this study, we investigated the adhesive properties of circulating plasma-derived and platelet-derived microvesicles (MVs) and their potential role in thrombus growth. The results showed that both types of MVs weakly bound fibrinogen but did not stably adhere to immobilized fibrinogen. Moreover, the presence of these MVs did not significantly affect thrombus formation. Therefore, MVs present in the plasma of healthy individuals are unlikely to directly contribute to thrombus formation under arterial flow conditions.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J. Favaloro
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marium Malik, Maha Al-Ghafry, Abraham Haimed, Julia Su, Maribel Lema, Linda Shore-Lessersson, Suchitra S. Acharya
Summary: This study analyzed and evaluated leukemia-associated coagulopathy in newly diagnosed pediatric leukemia patients using CCTs and ROTEM. The results showed that fibrinogen and platelets played a significant role in causing coagulopathies in this population. This suggests the utility of using CCTs and ROTEM in the pediatric population to evaluate hemostatic function and guide blood product replacement.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Mohammad M. Elahi, Alexandra N. Witt, Edward L. G. Pryzdial, Paul B. McBeth
Summary: Thrombotic disease may be underdiagnosed in microgravity conditions, and the underlying factors are still poorly understood. A case of internal jugular vein thrombosis was recently diagnosed in a low-risk female astronaut, and six out of ten additional crew members showed risk factors for jugular venous flow. Observations in space and studies on Earth suggest that microgravity affects blood flow, coagulation, and vascular function.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Stian Ingemann-Molden, Christina Krogner Caspersen, Nanna Rolving, Anette Arbjerg Hojen, Frederikus A. Klok, Erik L. Grove, Barbara Cristina Brocki, Jane Andreasen
Summary: This study found that no single PROM covered all aspects considered important by PE patients. PROMs recommended in the ICHOM core set covered most aspects, but worrisome thoughts, hypervigilance around symptoms, and uncertainty of illness were not covered.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Haomin Yan, Tsutomu Sasaki, Yasufumi Gon, Kumiko Nishiyama, Hideaki Kanki, Hideki Mochizuki
Summary: The incidence of cancer-associated stroke has increased with the prolonged survival times of cancer patients. In this study, the researchers focused on the driver gene KRAS and found that KRAS mutations exacerbated neurological deficits after stroke and promoted tumor growth. They also identified the upregulation of pro-inflammatory responses and the promotion of STAT3 phosphorylation in mice with KRAS mutations. Additionally, the researchers found that colorectal cancer patients with stroke onset within 3 months after cancer diagnosis had a worse prognosis.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Tomoki Togashi, Satomi Nagaya, Makiko Meguro-Horike, Haruto Matsumoto, Yuta Imai, Koichi Yamaguchi, Yoshinari Fujii, Haruka Moriya, Yuika Kikuchi, Ibuki Yasuda, Shin-ichi Horike, Eriko Morishita
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marta Najarro, Winnifer Briceno, Carmen Rodriguez, Alfonso Muriel, Sara Gonzalez, Ana Castillo, Ignacio Jara, Parth Rali, Catalin Toma, Behnood Bikdeli, David Jimenez
Summary: The CPES score is a useful tool in identifying the risk of hemodynamic deterioration in normotensive patients with acute PE, with acceptable C-statistic, excellent specificity, and low positive predictive value.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Lei Liu, Huifang Xu, Jian Wang, Haiyan Wang, Saisai Ren, Qian Huang, Mingyan Zhang, Hui Zhou, Chunyan Yang, Lu Jia, Yu Huang, Hao Zhang, Yanling Tao, Ying Li, Yanan Min
Summary: This study investigated the gut microbiota metabolites and cytokines, chemokines, and growth factors in patients with ITP and found their association with treatment responsiveness. The findings suggest that imbalanced secretion of cyto(chemo)kins/growth factors and inadequate levels of TMAO are characteristic of patients with ITP.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Roxanne Mcknight, Mohammad Salameh, Lee Ann Jones, Greta Anton, Lindsay Carter
Summary: This study evaluated the safety of fixed-dose heparin titration boluses in underweight patients with VTE. The results showed that although underweight patients required more frequent holding of heparin, there was no significant increase in bleeding risk.
THROMBOSIS RESEARCH
(2024)